2020年10月30日 · In November 2019, the Food and Drug Administration granted fast-track designation to investigation of neflamapimod to treat Lewy body dementia. As yet, no drugs have been approved by the FDA for treatment of the disease. The trial called AscenD-LB, is sponsored by EIP Pharma and involved patients 55 years and older.

This month we are highlighting updates from recent studies, along with new opportunities to participate in trials of potential new medications and diagnostic tests. New Data on LBD Caregiver Health. Providing care for a person with Lewy body dementia (LBD) has some unique challenges.

2024 has been an exciting year for clinical trials for people with Lewy body dementia (LBD). Over the past year, you have heard a lot from the Lewy Body Dementia Association (LBDA) about two Phase 2 clinical trials of experimental drugs in people with Dementia with Lewy bodies (DLB) – SHIMMER, a trial of the investigational drug CT1812, and ...

Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia.

Because it is not easy to accurately diagnose, affects so many, and early attention can make a world of difference, we want everyone to join together to raise awareness about Lewy body dementia (LBD) and improve the quality of life for those living with Lewy. Explore our new store featuring t-shirts, hoodies, hats, mugs, and more.

2023年9月21日 · Four new papers introduce two candidates: DOPA decarboxylase (DDC), the enzyme that converts levodopa into dopamine, and mitochondrial DNA damage. People with Lewy body disease (LBD) make ample DOPA decarboxylase (DDC). High DDC in CSF or blood distinguishes LBD from controls with up to 91 percent accuracy.

2021年2月15日 · A second new LBD signal was detected within the lysosomal TMEM175 gene on chromosome 4p16.3, a known Parkinson’s disease risk locus 12.

2021年11月12日 · Recent studies indicate that the adaptive immune system plays a role in Lewy body dementia (LBD). However, the mechanism regulating T cell brain homing in LBD is unknown. Here, we observed T cells adjacent to Lewy bodies and dopaminergic neurons in postmortem LBD brains. Single-cell RNA sequencing o …

The Lewy Body Dementia Resource Center was formed for the purpose of raising crucial awareness of Lewy body dementia (LBD) and to offer urgently needed help in New York for the many families who have lacked the services they need …

2023年5月1日 · Lewy Body Dementia is the second most frequent neurodegenerative illness proven to cause dementia, after Alzheimer's disease (AD). It is believed to be vastly underdiagnosed, as there is a significant disparity between the number of cases diagnosed clinically and those diagnosed via neuropathology at the time of postmortem autopsy.